Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage.

Competing Interests: SP and MH do contract research on the testing of vaccinee serum samples for neutralising activity against SARS-CoV-2 for Valneva, unrelated to this work. GMNB served as an advisor for Moderna and SP served as an advisor for BioNTech, unrelated to this work. All other authors declare no competing interests. SP acknowledges funding for this project by the German Federal Ministry of Education and Research (01KI2006D), the EU project UNDINE (grant agreement number 101057100), the Ministry for Science and Culture of Lower Saxony (14-76103-184, MWK HZI COVID-19), and the German Research Foundation (PO 716/11-1 and PO 716/14-1). H-MJ received funding from the German Federal Ministry of Education and Research (01KI2043, NaFoUniMedCovid19-COVIM 01KX2021), Bavarian State Ministry for Science and the Arts; and DFG through the research training groups RTG1660 and TRR130, the Bayerische Forschungsstiftung (Project CORAd), and the Kastner Foundation. GMNB acknowledges funding by the German Center for Infection Research (grant number 80018019238) and a European Regional Development Fund (Defeat Corona, ZW7-8515131). The funding sources had no role in study design, data collection, data analysis, data interpretation, writing of the Correspondence, or the decision to submit the manuscript for publication. We did not receive payment by a pharmaceutical company or other agency to write this Correspondence. We were not precluded from accessing data in the study and we accept responsibility to submit for publication.